Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on Equity

Viking Therapeutics (VKTX) Return on Capital Employed (2016 - 2025)

Viking Therapeutics' Return on Capital Employed history spans 11 years, with the latest figure at 0.6% for Q4 2025.

  • For Q4 2025, Return on Capital Employed fell 44.0% year-over-year to 0.6%; the TTM value through Dec 2025 reached 0.6%, down 44.0%, while the annual FY2025 figure was 0.53%, 29.0% down from the prior year.
  • Return on Capital Employed for Q4 2025 was 0.6% at Viking Therapeutics, down from 0.36% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.13% in Q2 2024 and bottomed at 0.6% in Q4 2025.
  • The 5-year median for Return on Capital Employed is 0.26% (2021), against an average of 0.29%.
  • The largest annual shift saw Return on Capital Employed skyrocketed 34bps in 2024 before it plummeted -44bps in 2025.
  • A 5-year view of Return on Capital Employed shows it stood at 0.27% in 2021, then plummeted by -81bps to 0.48% in 2022, then surged by 41bps to 0.28% in 2023, then soared by 40bps to 0.17% in 2024, then crashed by -259bps to 0.6% in 2025.
  • Per Business Quant, the three most recent readings for VKTX's Return on Capital Employed are 0.6% (Q4 2025), 0.36% (Q3 2025), and 0.26% (Q2 2025).